Metastatic Pancreas Cancer Clinical Trial
Official title:
Phase II Trial of in Situ Tumor Vaccination Using Durvalumab and "Booster" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy
Research Hypothesis: The combination of ionizing radiation and immunotherapy (durvalumab) is
well tolerated and stimulates a clinically significant pancreas-cancer specific immune
response.
The primary objective will be to evaluate whether the combination of RT and durvalumab can
improve median PFS compared to chemotherapy historical control data in metastatic pancreas
cancer patients who have progressed through first-line chemotherapy.
The primary intent of RT in this study is to augment a pancreatic cancer-specific immune
response when given with durvalumab.
This clinical trial will use the combination of ionizing radiation and immunotherapy durvalumab (MEDI4736). It is the investigators hypothesis that this combination of ionizing radiation and immunotherapy is well tolerated and stimulates a clinically significant pancreas-cancer specific immune response. This trial's primary objective will be to evaluate whether the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy. The study population includes the metastatic pancreatic adenocarcinoma patients who have progressed through first-line chemotherapy. The number of subjects proposed to complete this study is 55. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03126435 -
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
|
Phase 3 | |
| Recruiting |
NCT01586611 -
A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer
|
Phase 3 | |
| Recruiting |
NCT04897854 -
Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer
|
Phase 3 |